Fig. 5

In vitro investigations of solanidine metabolism. Formation of OH-solanidine (m/z 414) in 11 recombinant CYP enzyme and control bactosome incubations (0.1 mg/mL) from solanidine 2 µM (a); Depletion of 10 nM solanidine and formation of OH-solanidine in HLM (0.2 mg/mL) and CYP2D6 (0.1 mg/mL) incubations (b); Effects of the CYP2D6 inhibitor paroxetine and CYP3A inhibitor ritonavir on the depletion of 0.1 µM solanidine (c) and subsequent formation of OH–solanidine (d) in HLMs (0.2 mg/mL); Effects of paroxetine on the depletion of 10 nM solanidine (e) and subsequent formation of OH-solanidine in HLMs (0.2 mg/mL) (f). CYP, cytochrome P450; HLMs, human liver microsomes